Scientific Program

It is based on the local time of Seoul, Korea. (UTC/ GMT +9:00)

* [KOR] = Sessions in Korean Updated as of October 10

Thursday, November 10

Waun Ki Hong Memorial Lecture

Date & Time 11/10(Thu) 10:40-11:20 Place Crystal Ballroom
  • ·
  • Searching for somatic mutations - one cell at a time

    Peter J. Park (Harvard Medical School, Boston, MA, USA)

Session 1 : Single-cell transcriptome and cancer biology

Date & Time 11/10(Thu) 08:40-10:20 Place Crystal Ballroom
  • ·
  • Interrogating the surfaceome of pancreatic cancer subtypes

    Tobiloba E. Oni (Whitehead Institute for Biomedical Research, Cambridge, MA, USA)

  • ·
  • Single-cell analysis reveals recurring programs in cancer microenvironment

    Jong-Eun Park (Korea Advanced Institute of Science and Technology, Korea)

  • ·
  • Examining cell state transitions induced by cancer therapies using single-cell RNA sequencing

    Luciane T. Kagohara (Johns Hopkins University, Baltimore, MD, USA)

  • ·
  • Understanding responses to immunotherapy using single cell transcriptomes

    Jeeyun Lee (Sungkyunkwan University School of Medicine, Korea)

Session 2 : Artificial intelligence and computational biology approach

Date & Time 11/10(Thu) 12:20-14:00 Place Crystal Ballroom
  • ·
  • Genetic interaction mapping for discovery of synthetic lethal drug targets in cancer

    Alice Berger (Fred Hutchinson Cancer Center, Seattle, WA, USA)

  • ·
  • AI-based cancer screening using liquid biopsy

    Eun-Hae Cho (GC Genome, Korea)

  • ·
  • 3D genome reorganization in cancer

    Martin Aryee (Dana Farber Cancer Institute, Boston, MA, USA)

  • ·
  • AI-powered biomarker development to predict the clinical outcomes of immuno-oncology agents

    Sehhoon Park (Sungkyunkwan University School of Medicine, Korea)

Session 3 : Functional genomics and proteomics

Date & Time 11/10(Thu) 14:20-16:00 Place Crystal Ballroom
  • ·
  • Functional genomics identified CHK1 as a promising target in homologous recombination proficient high grade serous ovarian cancer

    Christina M. Annunziata (National Cancer Institute in Bethesda, MD, USA)

  • ·
  • Metabolic dysregulation leads to better response to cancer immunotherapy

    Joo Sang Lee (Sungkyunkwan University School of Medicine, Korea)

  • ·
  • Loss of nuclear alpha-catenin leads to ATR activation and contributes to poor outcome and chemoresistance in triple negative breast cancer

    John D. Carpten (Keck School of Medicine of USC, Los Angeles, CA, USA)

  • ·
  • Functional assessment of patient-derived mutations using CRISPR-Cas system

    Yongsub Kim (University of Ulsan College of Medicine, Korea)

Session 4 : Novel epigenetic therapeutic strategies

Date & Time 11/10(Thu) 16:20-18:00 Place Crystal Ballroom
  • ·
  • Combining demethylating agents with immune checkpoint inhibition to treat refractory malignancies: Promise and pitfalls

    Casey O’Connell (Keck School of Medicine of USC, Los Angeles, CA, USA)

  • ·
  • Cancer reversion

    Kwang-Hyun Cho (Korea Advanced Institute of Science and Technology, Korea)

  • ·
  • Epigenetic changes: Targets and biomarkers

    James G. Herman (UPMC Hillman Cancer Center, Pittsburgh, PA, USA)

  • ·
  • Epigenetic code in health and diseases

    Sung Hee Baek (Seoul National University College of Natural Sciences, Korea)

Luncheon Symposium 1 – Boryung [KOR]

Date & Time 11/10(Thu) 11:20-12:00 Place Crystal Ballroom
  • ·
  • Lurbinectedin for the treatment of small cell lung cancer

    Bong-Seog Kim (Boryung Co. Ltd., Korea)

Luncheon Symposium 2 – ONO/BMS

Date & Time 11/10(Thu) 11:20-12:00 Place Emerald Room
  • ·
  • The optimal option with long-term survival and tolerability in advanced (1L) GC/GEJ EAC and melanoma: nivolumab based therapies

    Wonyoung Choi (National Cancer Center, Korea)

Luncheon Symposium 3 - Roche [KOR]

Date & Time 11/10(Thu) 11:20-12:00 Place Sapphire Ballroom
  • ·
  • Demonstrated efficacy and long term safety about Bevacizumab in CRC

    Ho Jung An (The Catholic University of Korea, St. Vincent’s Hospital, Korea)

Friday, November 11

Session 5 : T-cell redirected therapies for cancer

Date & Time 11/11(Fri) 08:30-10:10 Place Crystal Ballroom
  • ·
  • Updated results of a phase I trial of PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer

    Naomi B. Haas (Penn Medicine Abramson Cancer Center, Philadelphia, PA, USA)

  • ·
  • A novel mechanism of targeting both LAG-3 and PD-L1 with a bispecific antibody

    Yoon Park (Korea Institute of Science and Technology, Korea)

  • ·
  • CAR T-cell based combination immunotherapy for solid tumors

    Prasad S. Adusumilli (Memorial Sloan Kettering Cancer Center, New York, NY, USA)

  • ·
  • Regulation of T cell immunity in lymph node and tumor

    Sang-Jun Ha (Yonsei University College of Life Science and Biotechnology, Korea)

Session 6 : Precision vaccination for cancer treatment

Date & Time 11/11(Fri) 10:30-12:10 Place Crystal Ballroom
  • ·
  • Vaccines targeting mutant KRAS neoantigens in combination with immune checkpoint blockade

    Neeha Zaidi (The Johns Hopkins Hospital, Baltimore, MD, USA)

  • ·
  • Determinants of neoantigen validity in cancer immunotherapy

    Kwoneel Kim (Kyung Hee University College of Science, Korea)

  • ·
  • Identification and characterization tumor-reactive T cells in malignant tumors through TCR analysis

    Bo Li (UT Southwestern Medical Center, Dallas, TX, USA)

  • ·
  • Characterization of tumor antigen-specific T cells in blood and tumors

    Eui-Cheol Shin (Korea Advanced Institute of Science and Technology, Korea)

Luncheon Symposium 4 – Lilly [KOR]

Date & Time 11/11(Fri) 12:20-13:00 Place Crystal Ballroom
  • ·
  • Take hope further with abemaciclib for patients with HR+, HER2- breast cancer

    Kyong Hwa Park (Korea University College of Medicine, Korea)

Luncheon Symposium 5 – MSD [KOR]

Date & Time 11/11(Fri) 12:20-13:00 Place Emerald Room
  • ·
  • Let 1L esophageal cancer patients start a whole new world with Pembrolizumab

    In-Ho Kim (The Catholic University of Korea College of Medicine, Korea)

KCA Symposium 1 : Novel cancer therapeutics [KOR]

Date & Time 11/11(Fri) 13:20-15:00 Place Crystal Ballroom
  • ·
  • PROTAC drugs in oncology: Concepts and cases

    Hwa Jin Lee (UPPThera, inc, Korea)

  • ·
  • Novel radiopharmaceutical therapies

    Joo Hyun O (The Catholic University of Korea College of Medicine, Korea)

  • ·
  • Cancer nanotheranostics

    Hyung-Jun Im (Seoul National University Graduate School of Convergence Science and Technology, Korea)

  • ·
  • New therapeutic modalities for the intractable cancers

    Jung Min Lee (Handong University School of Life Sciences, Korea)

KCA Symposium 2 : Precision radiotherapy with response prediction and real-time adaptation [KOR]

Date & Time 11/11(Fri) 13:20-15:00 Place Emerald Room
  • ·
  • Auto-contouring and online adaptive radiotherapy

    Jin Sung Kim (Yonsei University College of Medicine, Korea)

  • ·
  • MRI-guided radiotherapy and adaptation

    Jun Won Kim (Yonsei University College of Medicine, Korea)

  • ·
  • Genomic biomarker of radiotherapy and response prediction

    Bum-Sup Jang (Seoul National University College of Medicine, Korea)

  • ·
  • Response prediction of radiotherapy with radiomics

    Jaeseung Shin (Samsung Medical Center, Korea)

KCA Symposium 3 : Diagnostic and therapeutic challenges in precision oncology [KOR]

Date & Time 11/11(Fri) 15:20-17:00 Place Crystal Ballroom
  • ·
  • Minimal residual disease in colorectal cancer

    Sae-Won Han (Seoul National University College of Medicine, Korea)

  • ·
  • Spatial transcriptomics of gastric cancers

    Tae-Min Kim (The Catholic University of Korea College of Medicine, Korea)

  • ·
  • The telomere maintenance mechanism spectrum and its dynamics in gliomas

    Chul-Kee Park (Seoul National University College of Medicine, Korea)

  • ·
  • Precision medicine-based platform trial: Innovative clinical trial design in the era of precision medicine

    Yeon Hee Park (Sungkyunkwan University School of Medicine, Korea)

KCA Symposium 4 : Surgical oncology for advanced solid tumors [KOR]

Date & Time 11/11(Fri) 15:20-17:00 Place Emerald Room
  • ·
  • Complete cytoreductive surgery for resetting PARPi or PD-1i-Resistant recurrent ovarian, fallopian tubal, peritoneal carcinoma

    Myong Cheol Lim (National Cancer Center, Korea)

  • ·
  • Role of intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis

    Jong-Han Kim (Korea University College of Medicine, Korea)

  • ·
  • Conversion surgery in unresectable pancreatic cancer

    Jin-Young Jang (Seoul National University College of Medicine, Korea)

  • ·
  • Surgical treatment for retroperitoneal sarcoma

    Kyo Won Lee (Sungkyunkwan University School of Medicine, Korea)